{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6"}],"title":"Stable Disease"},{"measurements":[{"groupId":"OG000","value":"10"}],"title":"Progressive Disease"},{"measurements":[{"groupId":"OG000","value":"4"}],"title":"Partial Response"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"20"}],"units":"Participants"}],"description":"Clinical responses to the combination of nivolumab, ipilimumab and hypofractionated radiation will be based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \\>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.","groups":[{"description":"Patients receive nivolumab IV over 30 minutes on day 1. Treatment repeats every 2 weeks for up to 12 courses and then every 4 weeks for an additional 8 courses in the absence of disease progression or unacceptable toxicity. Patients also receive ipilimumab IV over 60 minutes on day 1. Treatment repeats every 6 weeks for up to 4 courses in the absence of disease progression or unacceptable toxicity. Beginning week 3, patients undergo 3 fractions of stereotactic body radiation therapy every other day in the absence of disease progression or unacceptable toxicity.\n\nNivolumab: Given IV\n\nIpilimumab: Given IV\n\nStereotactic Body Radiation Therapy: Undergo SBRT","id":"OG000","title":"Treatment (Nivolumab, Ipilimumab, SBRT)"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"Up to 4 years","title":"Objective Response Rate (ORR)","type":"SECONDARY","unitOfMeasure":"Participants"}